My NCBISign In

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 102

    1.

    Pathological cell-cell interactions are necessary for striatal pathogenesis in a conditional mouse model of Huntington's disease.

    Gu X, André VM, Cepeda C, Li SH, Li XJ, Levine MS, Yang XW.

    Mol Neurodegener. 2007 Apr 30;2:8.PMID: 17470275 [PubMed]Related articlesFree article

    2.

    Pathological cell-cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice.

    Gu X, Li C, Wei W, Lo V, Gong S, Li SH, Iwasato T, Itohara S, Li XJ, Mody I, Heintz N, Yang XW.

    Neuron. 2005 May 5;46(3):433-44.PMID: 15882643 [PubMed - indexed for MEDLINE]Related articles

    3.

    Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice.

    Gray M, Shirasaki DI, Cepeda C, André VM, Wilburn B, Lu XH, Tao J, Yamazaki I, Li SH, Sun YE, Li XJ, Levine MS, Yang XW.

    J Neurosci. 2008 Jun 11;28(24):6182-95.PMID: 18550760 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.

    Zhang H, Li Q, Graham RK, Slow E, Hayden MR, Bezprozvanny I.

    Neurobiol Dis. 2008 Jul;31(1):80-8. Epub 2008 Apr 16.PMID: 18502655 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Altered NMDA receptor trafficking in a yeast artificial chromosome transgenic mouse model of Huntington's disease.

    Fan MM, Fernandes HB, Zhang LY, Hayden MR, Raymond LA.

    J Neurosci. 2007 Apr 4;27(14):3768-79.PMID: 17409241 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Neocortical expression of mutant huntingtin is not required for alterations in striatal gene expression or motor dysfunction in a transgenic mouse.

    Brown TB, Bogush AI, Ehrlich ME.

    Hum Mol Genet. 2008 Oct 15;17(20):3095-104. Epub 2008 Jul 16.PMID: 18632688 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Interaction of postsynaptic density protein-95 with NMDA receptors influences excitotoxicity in the yeast artificial chromosome mouse model of Huntington's disease.

    Fan J, Cowan CM, Zhang LY, Hayden MR, Raymond LA.

    J Neurosci. 2009 Sep 2;29(35):10928-38.PMID: 19726651 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Corticostriatal synaptic function in mouse models of Huntington's disease: early effects of huntingtin repeat length and protein load.

    Milnerwood AJ, Raymond LA.

    J Physiol. 2007 Dec 15;585(Pt 3):817-31. Epub 2007 Oct 18.PMID: 17947312 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Alterations in N-methyl-D-aspartate receptor sensitivity and magnesium blockade occur early in development in the R6/2 mouse model of Huntington's disease.

    Starling AJ, André VM, Cepeda C, de Lima M, Chandler SH, Levine MS.

    J Neurosci Res. 2005 Nov 1;82(3):377-86.PMID: 16211559 [PubMed - indexed for MEDLINE]Related articles

    10.

    Mitochondrial sensitivity and altered calcium handling underlie enhanced NMDA-induced apoptosis in YAC128 model of Huntington's disease.

    Fernandes HB, Baimbridge KG, Church J, Hayden MR, Raymond LA.

    J Neurosci. 2007 Dec 12;27(50):13614-23.PMID: 18077673 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Polyglutamine-modulated striatal calpain activity in YAC transgenic huntington disease mouse model: impact on NMDA receptor function and toxicity.

    Cowan CM, Fan MM, Fan J, Shehadeh J, Zhang LY, Graham RK, Hayden MR, Raymond LA.

    J Neurosci. 2008 Nov 26;28(48):12725-35.PMID: 19036965 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Mitochondria and Huntington's disease pathogenesis: insight from genetic and chemical models.

    Browne SE.

    Ann N Y Acad Sci. 2008 Dec;1147:358-82. Review.PMID: 19076457 [PubMed - indexed for MEDLINE]Related articles

    13.

    Expanded-polyglutamine huntingtin protein suppresses the secretion and production of a chemokine (CCL5/RANTES) by astrocytes.

    Chou SY, Weng JY, Lai HL, Liao F, Sun SH, Tu PH, Dickson DW, Chern Y.

    J Neurosci. 2008 Mar 26;28(13):3277-90.PMID: 18367595 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration.

    Strand AD, Baquet ZC, Aragaki AK, Holmans P, Yang L, Cleren C, Beal MF, Jones L, Kooperberg C, Olson JM, Jones KR.

    J Neurosci. 2007 Oct 24;27(43):11758-68.PMID: 17959817 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Excitotoxic neuronal death and the pathogenesis of Huntington's disease.

    Estrada Sánchez AM, Mejía-Toiber J, Massieu L.

    Arch Med Res. 2008 Apr;39(3):265-76. Review.PMID: 18279698 [PubMed - indexed for MEDLINE]Related articles

    16.

    Dopaminergic signaling and striatal neurodegeneration in Huntington's disease.

    Tang TS, Chen X, Liu J, Bezprozvanny I.

    J Neurosci. 2007 Jul 25;27(30):7899-910.PMID: 17652581 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Neuroprotective effects of inositol 1,4,5-trisphosphate receptor C-terminal fragment in a Huntington's disease mouse model.

    Tang TS, Guo C, Wang H, Chen X, Bezprozvanny I.

    J Neurosci. 2009 Feb 4;29(5):1257-66.PMID: 19193873 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.
    19.

    Diminished hippocalcin expression in Huntington's disease brain does not account for increased striatal neuron vulnerability as assessed in primary neurons.

    Rudinskiy N, Kaneko YA, Beesen AA, Gokce O, Régulier E, Déglon N, Luthi-Carter R.

    J Neurochem. 2009 Oct;111(2):460-72. Epub 2009 Aug 17.PMID: 19686238 [PubMed - indexed for MEDLINE]Related articles

    20.

    A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse.

    Chopra V, Fox JH, Lieberman G, Dorsey K, Matson W, Waldmeier P, Housman DE, Kazantsev A, Young AB, Hersch S.

    Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16685-9. Epub 2007 Oct 9.PMID: 17925440 [PubMed - indexed for MEDLINE]Related articlesFree article

    Display Settings:

    Format
    Items per page
    Sort by

    Send to:

    Choose Destination
    Write to the Help Desk